{"nctId":"NCT04603924","briefTitle":"Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients","startDateStruct":{"date":"2020-10-07","type":"ACTUAL"},"conditions":["COVID-19"],"count":49,"armGroups":[{"label":"ANA001","type":"EXPERIMENTAL","interventionNames":["Drug: Niclosamide"]},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Niclosamide","otherNames":["ANA001"]},{"name":"Placebo","otherNames":["Matching Placebo to ANA001"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Provide written informed consent prior to performing study procedures\n2. Hospitalized.\n3. Male or female ≥18 years of age\n4. Positive for severe acute respiratory syndrome coronavirus 2\n5. Presence of symptoms of lower respiratory tract infection (LRTI) including at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, or more significant lower respiratory tract symptoms, including shortness of breath\n6. At least 1 of the following: respiratory rate (RR) ≥20 breaths per minute, room air oxygen saturation (SpO2) \\<98%, requirement for supplemental oxygen, heart rate (HR) ≥90 beats per minute, or temperature \\>38.3°C\n7. Women of childbearing potential must agree to abstinent or use at least 1 form of contraception not including hormonal contraception from the day of screening through Day 30\n\nKey Exclusion Criteria:\n\n1. Hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours)\n2. Patient is not anticipated to survive \\>48 hours OR is under palliative care\n3. Evidence of critical illness, defined by at least 1 of the following:\n\n   * Respiratory failure requiring at least 1 of the following:\n\n     1. Endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula\n     2. Noninvasive positive pressure ventilation (NIPVV), OR\n     3. Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of respiratory failure\n   * Shock (defined by systolic blood pressure (BP) \\<90 mm Hg, or diastolic blood pressure (BP) \\<60 mm Hg or requiring vasopressors), OR\n   * Multi-organ dysfunction/failure\n4. Severe central nervous system (CNS) conditions\n5. Chronic kidney disease requiring dialysis\n6. Known allergy to the study drug or salicylate containing medications.\n7. Suspected and/or confirmed pregnancy or breastfeeding\n8. Current or planned participation in any other clinical trial of a treatment being developed under a US investigational new drug (IND) or emergency use authorization (EUA).\n9. Patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (Mabs) or plasma transfusions) for chronic disease conditions.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Experiencing TEAEs","description":"Incidence of Treatment Emergent Adverse Events (TEAEs)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Experiencing TESAEs","description":"Incidence of Treatment Emergent Serious Adverse Events (TESAEs)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time to Hospital Discharge","description":"Median time until patient is discharged from hospital. Discharge is defined as a score of 1 or 2 in the WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating \"No clinical or virological evidence of infection\" and 8 indicating \"Death\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.03","spread":null},{"groupId":"OG001","value":"13.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time to 2-point Improvement WHO Clinical Improvement Scale","description":"Median Time to 2-point Improvement in WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating \"No clinical or virological evidence of infection\" and 8 indicating \"Death\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":null},{"groupId":"OG001","value":"13.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time to Resolution of COVID-19 Symptoms","description":"Median time (in days) to resolution of subjective symptoms assessed by the Investigator to be potentially due to COVID-19 including: fever, cough (productive or non-productive), sore throat, malaise, headache, muscle pain, gastrointestinal symptoms (i.e., nausea, vomiting, or diarrhea), shortness of breath (with or without exertion), and respiratory distress","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time to Time-to-Viral Load Undetectable","description":"Median number of days to viral load undetectable by nasopharyngeal (NP) swab","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.09","spread":null},{"groupId":"OG001","value":"13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"AUC 0-t (h*ng/mL)","description":"Area under the drug concentration (h\\*ng/mL) (AUC) vs time curve on Days 1 and 2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1728.6","spread":"1410.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2839.0","spread":"1702.25"}]}]}]},{"type":"SECONDARY","title":"Cmax (ng/mL)","description":"Maximum post dose plasma drug concentration on \\[Cmax (ng/mL)\\] Days 1 and 2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"348.06","spread":"212.343"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"435.91","spread":"204.059"}]}]}]},{"type":"SECONDARY","title":"Tmax (h)","description":"Time to maximum post dose plasma drug concentration on \\[Tmax (h)\\] Days 1 and 2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.884","spread":"2.3139"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.983","spread":"2.4002"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":22},"commonTop":["Insomnia","Anxiety","Constipation","Nausea","Hypocalcaemia"]}}}